ArticleiScience2026
Elevated circulating BACE2 captures chronic glycemic burden and enhances the clinical identification of type 2 diabetes.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although β-site amyloid precursor protein-cleaving enzyme 2 (BACE2) is implicated in β-cell physiology, its clinical relevance in metabolic dysfunction remains unclear. Here, we investigated the clinical significance of circulating BACE2 in type 2 diabetes (T2D). Serum BACE2 was measured by enzyme-linked immunosorbent assay (ELISA) in 161 patients with T2D and 134 individuals with normal glucose tolerance. Circulating BACE2 was significantly elevated in T2D and independently associated with the presence of disease, with individuals in the highest quartile showing a 7.22-fold higher adjusted likelihood of T2D. BACE2 levels correlated positively with insulin resistance and dyslipidemia, with HbA1c emerging as the strongest determinant. Notably, BACE2 levels decreased following oral glucose loading in T2D, suggesting dynamic regulation in response to metabolic stimuli. Combining BACE2 with HOMA-IR markedly improved diagnostic performance (AUC 0.912 versus 0.712 for BACE2 alone). These findings identify circulating BACE2 as a biomarker reflecting chronic glycemic burden and metabolic stress in T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.